Astellas Obtains Additional Indication For Prograf in Japan; Pfizer, GSK, Novartis Also Gain
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma received July 7 additional indication approval for its best-selling immunosuppressant Prograf (tacrolimus) for moderate to severe refractory ulcerative colitis in Japan
You may also be interested in...
Novartis Renin Inhibitor Rasilez Approved In China For Hypertension
SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S
Novartis Renin Inhibitor Rasilez Approved In China For Hypertension
SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S
Astellas Submits Pediatric Data To U.S. FDA For Flomax Exclusivity; Announces JV With Maxygen
TOKYO - Astellas Pharma July 1 said its U.S. licensee for Flomax (tamsulosin), Boehringer Ingelheim Pharmaceuticals submitted data to U.S. FDA from a study on pediatric patients with neurogenic bladders - apparently to fend off generics offerings when the drug's patent protection expires later this year